Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

First-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) can improve efficacy of metastatic colorectal cancer (MCRC), KRAS wild-type and mutant. Prognostic relevance of KRAS genotype was evaluated in patients unfit for FIr-B/FOx, treated with conventional medical treatments. Consecutive MCRC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063538/
https://www.ncbi.nlm.nih.gov/pubmed/24715238
http://dx.doi.org/10.3892/ijo.2014.2369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063538/
https://www.ncbi.nlm.nih.gov/pubmed/24715238
http://dx.doi.org/10.3892/ijo.2014.2369

Ejemplares similares